The contribution of gut microbiome to liver carcinogenesis after SVR

The contribution of gut microbiome to liver carcinogenesis after SVR - Gut microbiome and liver carcinogenesis after SVR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026154

Enrollment

Registered

2017-02-15

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who who will visit as outpatient or be admitted to Nagasaki university hospital. 2. Patients providing written informed consent with their own will. 3. Patients who didn't progress to liver carcinogenesis 5 years after anti-HCV therapy with SVR, or patients who progress to liver carcinogenesis 6 months after anti-HCV therapy with SVR.

Exclusion criteria

Exclusion criteria: 1. Patients with some diffuse lesions in large colon. 2. Patients with severe general complications 3. Patients who were judged to be inappropriate for this study.

Design outcomes

Primary

Measure	Time frame
To analysis the gut microbiome in the patients with or without liver carcinogenesis after SVR.	—

Countries

Japan

Contacts

Public ContactSatoshi Miuma

Nagasaki University Hospital Department of Gastroenterology and Hepatology

miuma1002@gmail.com0958197481

Outcome results